Aura Biosciences
Filed with the SEC on · accession 0001193125-26-452620
AURA filed a 8-K (current report) with the SEC on Nov 9, 2026. Aura Biosciences reported its financial results for the quarter ended September 30, 2026, and updated its corporate presentation for investor meetings.
Aura Biosciences reported its financial results for the quarter ended September 30, 2026, and updated its corporate presentation for investor meetings. The company also reiterated its expected cash runway into the first half of 2029.
✦ Ask GOAX AI about this filing — what it means for AURA, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for AURA?
Click hereAURA filed a 8-K (SEC filing). Aura Biosciences reported its financial results for the quarter ended September 30, 2026, and updated its corporate presentation for investor meetings. The company also reiterated its expected cash runway into the first half of 2029.
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Get alerts when AURA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days